Merck & Co. EPS (Basic) decreased by 47.8% to $1.21 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 18.2%, from $1.48 to $1.21. Over 3 years (FY 2021 to FY 2025), EPS (Basic) shows an upward trend with a 14.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates improved profitability or a reduction in share count, while a decrease suggests declining earnings or equity dilution.
Basic earnings per share represents the portion of a company's profit allocated to each outstanding share of common stoc...
Investors compare this across large-cap technology peers to assess the efficiency of earnings generation relative to the equity base.
is_eps_basic| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.48 | $1.80 | $1.32 | $1.70 | $1.55 | $1.28 | $1.18 | $1.11 | -$2.35 | $1.87 | $1.88 | $2.15 | $1.25 | $1.48 | $2.01 | $1.76 | $2.32 | $1.21 |
| QoQ Change | — | +275.0% | -26.7% | +28.8% | -8.8% | -17.4% | -7.8% | -5.9% | -311.7% | +179.6% | +0.5% | +14.4% | -41.9% | +18.4% | +35.8% | -12.4% | +31.8% | -47.8% |
| YoY Change | — | — | — | — | +222.9% | -28.9% | -10.6% | -34.7% | -251.6% | +46.1% | +69.4% | +191.5% | -33.2% | — | +6.9% | -18.1% | +85.6% | -18.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.